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Abstract 
Circulating levels of cholesterol derive from either endogenous production or intestinal 
absorption of dietary and biliary cholesterol. Niemann-Pick C1-Like 1 (NPC1L1) is a 
transmembrane protein that plays a key role in the intestinal absorption of cholesterol 
by facilitating its uptake through vesicular endocytosis. NPC1L1 is the molecular target 
of ezetimibe which binds its extracellular loop and inhibits sterol absorption without 
affecting the absorption of other molecules. Ezetimibe significantly reduces plasma 
levels of total and low density lipoprotein cholesterol (LDL-C) as monotherapy or when 
added to statins, the association with a low dose of statin is of particular interest for 
patients experiencing statin-related side effects. The recent results of the IMPROVE-IT 
study, which evaluated the cardiovascular effect of ezetimibe added to simvastatin 
therapy in subjects who had had an acute coronary syndrome and with LDL-C levels 
within the recommended range, showed that a further LDL-C lowering reduced the 
incidence of cardiovascular events. To date, ezetimibe represents the only inhibitor of 
NPC1L1 available for clinical use, however, novel amino-ß-lactam ezetimibe 
derivatives have been synthesized and their efficacy to inhibit NPC1L1 protein and 
decrease plasma cholesterol levels is under evaluation.  
 
Keywords: NPC1L1; cholesterol; cholesterol absorption; ezetimibe; LDL-C; 
cardiovascular disease 
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Introduction 
Niemann-Pick C1L1 (NPC1L1) protein plays a central role in the intestinal absorption 
of cholesterol and is a key determinant of plasma cholesterol levels1, 2. In humans, 
NPC1L1 is present also in the liver, where it prevents excessive loss of biliary 
cholesterol3. 
While NPC1L1 overexpression increases cholesterol uptake in cells4, NPC1L1 
knockout mice were protected against diet-induced hypercholesterolemia, as a 
consequence of the defective intestinal uptake of cholesterol5. In addition, naturally 
occurring loss of function mutations of NPC1L1 are associated with lower LDL-C levels 
and a reduced risk of coronary heart disease6. The observation that ezetimibe 
decreases intestinal cholesterol absorption via NPC1L1 inhibition, thus resulting in a 
reduction of plasma LDL-C levels by about 20% in monotherapy7, paved the road for a 
novel complementary approach for the treatment of hypercholesterolemia aimed at 
controlling endogenous cholesterol synthesis in the liver (statins) as well as dietary 
cholesterol absorption (ezetimibe). 
Adding ezetimibe to established statin therapy results in a further incremental LDL-
C lowering of 15%–20%8; the recent results of the IMPROVE-IT trial showed that 
ezetimibe, given in combination with simvastatin, reduced the combined 
cardiovascular outcome compared with simvastatin alone in acute coronary syndrome 
patients as a result of the additional LDL-C lowering obtained9. The aim of this review 
is to discuss the biological consequences of NPC1L1 inhibition on cholesterol 
homeostasis and the key aspects to be considered when designing novel ezetimibe 
analogs as potential cholesterol absorption inhibitors. 
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Biology of NPC1L1 
Cholesterol homeostasis 
Cholesterol plays a key role in cell biology, as it is a main constituent of cell 
membranes, and in the body, as it is required for the formation of bile salts and is the 
precursor of steroid hormones and vitamin D. Due to its importance, there are several 
cellular and systemic mechanisms able to tightly regulate the abundance of 
cholesterol, including intestinal absorption, endogenous biosynthesis, reverse 
cholesterol transport and biliary/intestinal excretion. Elevated plasma cholesterol 
levels represent a risk factor for atherosclerosis and cardiovascular disease. 
Intestinal cholesterol absorption is a complex multistep process regulated by multiple 
genes; among them, NPC1L1, which is involved in cholesterol uptake2, and ATP-
binding cassette transporters ABCG5 and ABCG8, that function as heterodimer and 
promote cholesterol efflux into the intestinal lumen for excretion10. Defects in the 
ABCG5/ABCG8 system are linked to sitosterolemia, a condition characterized by high 
plasma levels of dietary sterols and premature coronary heart disease10. 
 
Expression, regulation and tissue distribution of NPC1L1 
NPC1L1 is a protein of 1,332 amino acids that plays a key role in the absorption 
of cholesterol; a truncated transcript has also been described, although its biological 
relevance is still not defined11, 12. NPC1L1 is a homolog of Niemann-Pick C1 (NPC1) 
protein which plays a key role in chaperoning lysosomal cholesterol and, when 
mutated, causes Niemann-Pick disease type 1, a severe disease characterized by the 
accumulation of cholesterol and glycolipids in lysosomes13. NPC1L1 is a plasma 
membrane protein containing 13 putative transmembrane domains, several N-linked 
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glycosylation sites in the extracellular loops of the protein and a sterol-sensing domain 
(SSD)12, 14, 15 (Figure 1). The SSD is a region of 180 amino acids that forms five 
membrane-spanning helices with short intervening loops; this region is conserved in 
several other proteins playing a critical role in cholesterol homeostasis16, 17. The 
extracellular N-terminal domain of NPC1L1, that in the absence of cholesterol is in a 
closed conformation, directly binds cholesterol, and this interaction is essential for 
NPC1L1-mediated cellular cholesterol uptake18, 19 (Figure 1).  
The cellular localization of NPC1L1 is strictly related to cholesterol content: when 
cells are enriched in cholesterol, NPC1L1 localizes in the endocytic recycling 
compartment; following cholesterol depletion it translocates to an apical-like 
subdomain at the cell surface, thus facilitating free cholesterol uptake20, 21. Also 
NPC1L1 expression is tightly regulated by cellular cholesterol content and depends on 
several transcription factors, including SREBP-2, LXRα, HNF4α and PPARs22-26. Mice fed 
a high cholesterol diet have very low levels of intestinal NPC1L1 mRNA27 associated to 
reduced expression of HNF4α and SREBP-226, 28; on the contrary, cholesterol 
deprivation significantly raises NPC1L1 mRNA levels in both intestine and liver, while 
increasing SREBP-2 mRNA expression28. Recently, the nuclear receptor liver receptor 
homolog-1 (LRH-1) has been shown to affect hepatic expression of NPC1L1, likely 
through a synergistic transcriptional activation in combination with SREBP-229. 
In addition to cholesterol, several other stimuli may modulate the expression of 
NPC1L1. As example, in mice, cholecystokinin, a peptide hormone responsible for the 
release of digestive enzymes and bile into the intestinal lumen, is known to raise 
plasma cholesterol levels by increasing cell-surface associated NPC1L1 in intestinal 
cells30, 31. In vitro, colecystokinin induces the activation of PI3K-Akt pathway that in 
turn facilitates the physical interaction of NPC1L1 with Rab11 and the subsequent 
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NPC1L1 translocation to the cell surface31. Also high glucose levels increase the 
cellular uptake of cholesterol in cultured intestinal cells; this effect is due to the 
modulation of cholesterol transporters present in intestinal epithelial cells, being 
NPC1L1 and CD36 upregulated and SR-BI downregulated32. Glucose also increases 
NPC1L1 promoter activity in cultured intestinal cells, thus suggesting a transcriptional 
regulation33; the effect of glucose seems to be dependent on glucose metabolism as 
well as the activation of cellular protein phosphatases33. Whether these mechanisms 
could account for the altered cholesterol absorption observed in diabetic patients34 
remains to be explored. 
In contrast to NPC1, which is highly expressed and widely distributed in various 
tissues35, NPC1L1 mRNA and protein are mostly expressed in the gastrointestinal 
tract, being the small intestine and especially enterocytes from the proximal 
(jejunum) region highly enriched in NPC1L114.  
While in mice and rats NPC1L1 expression is restricted to the intestine5, in 
humans and in non-human primates, NPC1L1 is also expressed in the liver, within the 
canalicular membrane of hepatocytes, where it facilitates cholesterol uptake, thus 
potentially preventing excessive loss of biliary cholesterol3. Opposing the function for 
NPC1L1 in the liver, ABCG5 and ABCG8 promote the removal of sterols from the body 
through biliary excretion36. The acquisition of hepatic NPC1L1 expression could 
represent an evolutionary advantage to locally control the cholesterol content in the 
membrane of hepatocytes, which appears to be a relevant factor for the canalicular 
membrane to limit the cytotoxic effect of biliary acids37.  
Recently, the possibility that epigenetics mechanisms could control NPC1L1 
transcription and differential tissue localization was proposed. In animal models, 
increased DNA methylation was observed in the colon compared with jejunum and 
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ileum and the treatment with a DNA methyltransferase inhibitor agent was associated 
with increased NPC1l1 expression in the colon38. A similar epigenetic mechanism was 
proposed to modulate also human NPC1L1 expression38.  
 
Mechanisms of NPC1L1-mediated intestinal cholesterol absorption 
Several pathways and multiple receptors/transporters are involved in intestinal 
cholesterol absorption1. As detailed above, NPC1L1 which is expressed at the apical 
membrane of enterocytes plays a crucial role in this process14. 
Several observations have suggested that the mechanism by which NPC1L1 
mediates cholesterol uptake is through a clathrin-dependent endocytosis:  
a) NPC1L1 cycles between plasma membrane and recycling endosome, a process 
coupled to cholesterol uptake that can be inhibited by blocking clathrin-mediated 
endocytosis20;  
b) caveolae-mediated endocytosis is not involved in the process of cholesterol 
absorption, as mice lacking caveolin-1 exhibit normal intestinal cholesterol 
absorption39; 
c) finally, NPC1L1 co-immunoprecipitates with proteins (a subunit of the adaptor 
protein complex AP2 and the clathrin heavy chain) essential for clathrin-dependent 
endocytosis21. NPC1L1 contains a YVNXXF internalization motif located at the 
cytoplasmic C-terminal tail, a sequence that is highly conserved among mammalian 
NPC1L1 proteins and is not present in the homolog NPC140. The binding of cholesterol 
to the N-terminal domain of NPC1L1 induces the dissociation of YVNXXF-containing 
region from plasma membrane thus enabling the binding of the clathrin adaptor 
Numb, that, in turn, recruits clathrin/AP2 complex for internalization40. 
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NPC1L1, following the binding of cholesterol to its N-terminal domain18, forms 
cholesterol-enriched membrane microdomains on plasma membrane by interacting 
with lipid raft proteins including flotillin; these microdomains function as carriers for 
bulk of cholesterol41. NPC1L1-flotillins containing microdomains might provide a 
cholesterol-enriched region required to initiate the process of NPC1L1 endocytosis. In 
fact, in the presence of high cholesterol levels, the sterol-sensing domain of NPC1L1 
might induce protein conformational changes promoting endocytosis41. The possibility 
that, during the assembly of these cholesterol-enriched microdomains, other unknown 
factors might be incorporated and activate the process of NPC1L1 endocytosis41, 
should be considered. NPC1L1 inhibitors limit the formation of these cholesterol-
enriched microdomains by disrupting the NPC1L1-flotillins complex41.  
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Human loss of function mutations of NPC1L1 and cardiovascular disease 
Given that pre-clinical data indicate the key relevance of NPC1L1 in determining 
cholesterol absorption, molecular approaches to inhibit NPC1L1 activity thus limiting 
cholesterol absorption and reducing plasma cholesterol levels have been explored42. A 
critical aspect to translate the relevance of NPC1L1 inhibition to the human context is 
the demonstration that this process results also in cardiovascular protection. While the 
gold standard is represented by a long clinical trial with cardiovascular hard events as 
endpoint, a parallel approach to estimate the potential efficacy of NPC1L1 targeting is 
the study of plasma lipid profile and cardiovascular outcome in subjects with naturally 
occurring DNA sequence variants that affect the activity/expression of NPC1L1. 
Although DNA sequence variants in NPC1L1 were associated with modest alterations 
in plasma LDL cholesterol levels43, a large screening in 7364 patients with coronary 
heart disease and in 14,728 controls without such disease identified 15 distinct 
NPC1L1 rare inactivating mutations6. Carriers of a single mutant NPC1L1 allele 
presented a significant reduction in plasma LDL-C levels (12 mg/dL) but, more 
importantly, they presented a relative reduction of 53% in coronary heart disease 
risk6. This finding represents an elegant demonstration that genetically determined 
lifelong lower activity of NPC1L1 is associated with cardiovascular protection. 
Extrapolation of genetic findings into pharmacology needs some caution, indeed while 
genetic data provides a lifelong NPC1L1 lower expression, pharmacological treatment 
will start later in life and be limited in time. Therefore, the benefit in terms of 
cardiovascular risk reduction (-53%) as a consequence of genetically driven (NPC1L1 
inactivating mutations) LDL-C reduction (-12mg/dL) will be much higher compared 
with the cardiovascular risk reduction observed in clinical trials with a similar degree 
of LDL-C reduction44-46. A finding which has been confirmed in all the analyses of lipid 
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lowering genes47.  
Human loss of function mutations of NPC1L1 and gallstone disease 
Preclinical observations point to a protective role for NPC1L1 on cholesterol 
gallstone disease as a consequence of the reduction in bile secretion of cholesterol. 
Even in this context, the genetic approach is instrumental to investigate the impact of 
NPC1L1 inhibition on gallstone disease. Loss of function variations of NPC1L1, 
although associated with reduced risk of ischemic vascular disease, were initially 
associated with a modest but significant increased risk of symptomatic gallstone 
disease48. However, this finding was not confirmed later, and indeed in a larger 
analysis, which included more than 100,000 subjects, no association between NPC1L1 
polymorphisms and the risk of gallstone disease was observed49. Similarly, a genome-
wide association study of symptomatic gallbladder disease among women failed to 
observed any association of NPC1L1 polymorphisms with symptomatic gallbladder 
disease (p=0.39)50. More importantly when the data from these three studies were 
combined, NPC1L1 inactivating variants were not associated with a significantly 
increased risk of symptomatic gallbladder disease. More importantly, this result is in 
line with data from pharmacological inhibition of NPC1L1 which excluded an increased 
risk of symptomatic gallbladder disease over an average 6-years follow-up in the 
IMPROVE-IT study9. 
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Experimental pharmacology of NPC1L1 inhibition 
Ezetimibe, a drug initially designed to inhibit cholesterol absorption for treating 
hypercholesterolemia, was later discovered to target NPC1L114, 51. Both oxysterols and 
ezetimibe inhibit the formation of NPC1L1-flotillin-cholesterol microdomains; however, 
in contrast to oxysterols which compete with cholesterol for the N-terminal domain of 
NPC1L1, ezetimibe binds to a region within a large extracellular domain (loop C) 
(Figure 1), which is distinct from the binding site of cholesterol and is located in the 
intestinal lumen52, thus inducing the dissociation of NPC1L1 from flotillin, preventing 
the formation of NPC1L1-flotillin-cholestrol microdomains41 and blocking the 
internalization of NPC1L1 and cholesterol in intestinal enterocytes53.  
NPC1L1-deficient mice (NPC1L1 KO) exhibit a significantly decreased absorption 
of cholesterol (-69%) compared with wild type mice. A similar extent of reduction in 
cholesterol absorption (-70%) is observed in wild type mice treated with ezetimibe14. 
More importantly NPC1L1 KO mice are completely resistant to diet-induced 
hypercholesterolemia and present plasma and hepatic cholesterol levels similar to 
those of wild type mice treated with ezetimibe5, 27. 
On the other hand, transgenic mice expressing human NPC1L1 in hepatocytes 
present a 30%-60% increase in plasma cholesterol, mainly due to the accumulation of 
apoE-rich HDL, together with the reduction in biliary cholesterol concentration; in 
these animals ezetimibe restore both biliary and plasma cholesterol levels3, 54. 
Ezetimibe is rapidly absorbed from the gastrointestinal tract and transformed 
into its glucuronides (Figure 2). The main metabolite in human plasma is a phenolic 
glucuronide that accounts for about 90% of total ezetimibe. This glucuronide localizes 
more avidly in the intestine compared with ezetimibe and exhibit similar or even 
higher cholesterol-lowering activity compared with the parent compound17, 55. The 
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plasma concentration-time profile of ezetimibe and its conjugated metabolite shows 
multiple peaks, indicating enterohepatic recycling56. 
Enterocytes isolated from NPC1L1-deficient mice do not exhibit detectable 
binding ability to radiolabeled ezetimibe glucuronide, in contrast to the high level of 
binding observed in enterocytes isolated from wild type mice51, clearly reaffirming that 
NPC1L1 is the direct molecular target of ezetimibe. 
The deficiency of NPC1L1 in atherosclerosis prone animals such as the apoE-/- 
mice is associated with a significantly reduced ability of these animals to absorb 
cholesterol compared with that of apoE-/-57. The most remarkable effect of NPC1L1 
deletion in this animal model is the almost complete protection from the development 
of atherosclerotic lesions; this effect is similar to that obtained in apoE-/- mice treated 
with ezetimibe57. 
Cholesterol feeding of NPC1L1-/-/LDLR-/- knockout mice genetically modified to 
overexpress human NPC1L1 only in the gastrointestinal tract resulted in a  
significantly increased cholesterol absorption, compared with the double knockout 
mice58, which was associated with increased apolipoprotein B100 and B48 secretion 
and plasma cholesterol levels58. These findings suggested that, at least in animal 
models, NPC1L1-mediated cholesterol absorption is a major determinant of 
atherogenic apoB-containing lipoproteins. 
The reduction of cholesterol absorption, promotes, as a feedback mechanism to 
maintain cholesterol homeostasis, the increase of reverse cholesterol transport 
(RCT)59, a process involved in the transport of  cholesterol from peripheral cells back 
to the liver. This mechanism is common in mice genetically manipulated to present 
reduced cholesterol absorption59, but is also observed in mice60, 61 and hamsters62 
following ezetimibe administration. These findings suggest that the inhibition of 
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cholesterol absorption may exert an atheroprotective effects also by promoting the 
removal of cholesterol excess from peripheral tissues. 
As the maintenance of cholesterol homeostasis is critical for several biological 
processes and cholesterol synthesis and absorption are inversely regulated to 
maintain cholesterol balance, it is not surprising that the inhibition of endogenous 
cholesterol absorption activates also a series of mechanistic feedbacks resulting in 
increased endogenous cholesterol synthesis63. Thus, while statins inhibit hepatic 
synthesis of cholesterol and increase cholesterol absorption markers, ezetimibe 
negatively affects cholesterol absorption but also increases cholesterol synthesis63. 
These pharmacological responses may reduce the efficacy of the single drugs, but also 
set the stage for combining the two pharmacological approaches with the aim of 
limiting both cholesterol absorption and synthesis. In this context, it is worth to 
mention that statins cause elevation of plasma PCSK9, a proprotein convertase that 
promotes LDLR degradation, and this effect can reduce the cholesterol-lowering 
efficacy of statins64. However, in healthy subjects, while a 2-week treatment with 
simvastatin (40 mg) resulted in the upregulation of circulating PCSK9 levels, neither 
ezetimibe alone nor the addition of ezetimibe to simvastatin induced an increase in 
PCSK9 levels65. This finding could perhaps be the consequence of the limited absolute 
LDL-C reduction induced by ezetimibe on the top of simvastatin which may not be 
enough to further upregulate PCSK9 expression. In line with this, modest LDL-C 
lowering such as that observed with simvastatin 10 mg does not increase PCSK9 
levels66. The observation that key players in cholesterol metabolism, including HMG-
CoA reductase, LDL-R, PCSK9 and NPC1L1 are cross-regulated depending on how 
cholesterol homeostasis is targeted, reinforce the rationale for the use of 
pharmacological approaches combining ezetimibe and a statin. 
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Clinical pharmacology of the NPC1L1 inhibitor ezetimibe 
Inhibition of NPC1L1 by ezetimibe and LDL-C lowering 
LDL-C lowering represents the primary target of therapy in the primary and 
secondary prevention of cardiovascular disease. Statins, which inhibit endogenous 
cholesterol biosynthesis, mainly in the liver, are the first-choice drug for the treatment 
of hypercholesterolemia67. The observation that the extent of plasma LDL-C reduction 
is directly associated with the decrease of cardiovascular diseases46 supports the need 
of novel pharmacological approaches beyond statins for patients with 
hypercholesterolaemia42, 68-70. Among them, ezetimibe possesses a mechanism of 
action that is complementary to that of statins, and thus the combination statin-
ezetimibe represents a successful approach to improve the management of 
hypercholesterolemia and the prevention of cardiovascular disease. In addition, the 
residual risk of recurrent cardiovascular events even with aggressive statin-based 
cholesterol-lowering therapies and concerns regarding the safety and adverse events 
observed with high-dose statins further supported the search for lipid-lowering 
therapies with a complementary mechanism of action71, 72.  
A large number of clinical trials have evaluated the effect of adding ezetimibe to 
statins, showing an average additional LDL-C levels reduction of about 20%42, 73-75 
(Table 1). These findings have been confirmed in a pooled analysis of over 21,000 
subjects from 27 clinical trials that compared the effect of statin versus statin plus 
ezetimibe and showed that the combination therapy was more effective at reducing 
LDL-C levels (treatment difference: -15.1%, p<0.0001)76. Overall, the lipid profile was 
greatly improved with the combination therapy compared to similar statin doses and 
in most of the cases also when higher statin doses were used. Furthermore, safety 
profiles were comparable among the treatments. 
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Moreover, a retrospective, observational study showed that both LDL-C lowering 
and goal attainment were significantly higher in patients with CHD or CHD risk-
equivalent treated with ezetimibe added to current statin therapy compared with 
patients who titrated the statin doses (-26% to 27% vs -8.8% to -9.8%)77. Finally, 
ezetimibe seems to have beneficial effect also on RCT in humans, similarly to what 
observed in animal models, resulting in an increased flux of cholesterol to feces in 
hyperlipidemic patients78. 
The higher efficacy of ezetimibe combined with statin for the treatment of 
atherogenic dyslipidemia has been recently confirmed also in diabetic patients. The 
RESEARCH (Recognized Effect of Statin and Ezetimibe therapy for Achieving LDL-C 
Goal) trial compared, in type 2 diabetic subjects who failed to achieve their LDL-C 
target, the 12-week effect of a high-potency statin plus ezetimibe (atorvastatin 10 mg 
or pitavastatin 1 mg + ezetimibe 10 mg) versus doubled dose of statin (atorvastatin 
20 mg or pitavastatin 2 mg)79. The combination ezetimibe+statin was more effective 
at reducing LDL-C levels than doubling the dose of statins (-24.6% vs -10.9%, 
respectively)79 and a significantly higher percentage of subjects reached their LDL-C 
goals in the group treated with ezetimibe+statin than in the group treated with a 
doubled statin dose (89.3% vs 51%, p<0.0001)79. In addition, the treatment with 
ezetimibe+statin improved the atherogenic plasma lipid profile more effectively than 
statin therapy, including a more pronounced reduction of small dense LDL levels  
(-20.5% vs -3.7%) and remnant-like particle cholesterol (-19.7% vs +5.5%)79. 
Diabetic patients have been suggested to benefit from combination therapy 
ezetimibe+statin more than non-diabetic subjects, as they seem to achieve 
significantly higher reduction in LDL-C and non-HDL-C; this might be due to a higher 
expression of NPC1L1 in diabetic patients, but a defined explanation is still lacking80. 
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Besides, it emerged that statin use may impair glucose tolerance and increase 
the risk of new-onset type 2 diabetes, although the benefits of cardiovascular risk 
reduction still largely exceeds the risk of incident diabetes81. On the contrary, current 
data suggest that ezetimibe ameliorates glycemic control and insulin sensitivity82. 
However, conclusive results are still lacking, as most clinical trials did not evaluate the 
impact of ezetimibe on glucose metabolism and commonly tested the effect of 
ezetimibe in combination with a statin82. An analysis of the IMPROVE-IT trial suggests 
that type 2 diabetic patients with a recent acute coronary syndrome may benefit from 
the addition of ezetimibe to a statin therapy: in fact, in this subgroup of patients, 
ezetimibe added to a statin lowered LDL-C more than the statin alone (43 mg/dL vs 
23 mg/dL) and reduced the relative cardiovascular risk by 14%83. In non-diabetics 
this effect was less evident, with a 2% relative risk reduction83. 
 
Inhibition of NPC1L1 by ezetimibe and inflammation 
Statins were proposed to have pleiotropic effects beyond lipid-lowering; among 
them, the ability to reduce inflammation, a process that play a crucial role in the 
atherogenic process84. Indeed, studies designed to evaluate the effect of ezetimibe on 
inflammatory markers in subjects at increased cardiovascular risk showed a decreased 
expression of markers of oxidative stress and inflammation85-87. This may suggest that 
the beneficial effect of ezetimibe on inflammation could depend on the degree of 
plasma cholesterol reduction achieved, further supporting the correlation between 
plasma cholesterol and the immuno-inflammatory status88-91. 
Conversely, no effects were observed on the amount of circulating microparticles 
or endothelial progenitor cells in subjects with coronary heart disease under 
antiplatelet therapy and treated with the combination ezetimibe/simvastatin, in spite 
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of a significant increase of endothelial function measured as flow-mediated 
dilatation92. A lack of effect on microparticles and endothelial progenitor cells by 
ezetimibe treatment was reported also in patients at high-risk for coronary heart 
disease93.  
 
Inhibition of NPC1L1 by ezetimibe and carotid and coronary atherosclerosis 
Some studies have raised concerns about the efficacy of ezetimibe treatment in 
the prevention of cardiovascular disease. The ENHANCE (Ezetimibe and Simvastatin in 
Hypercholesterolemia Enhances Atherosclerosis Regression) trial evaluated the effect 
of the administration of 10 mg ezetimibe in combination with 80 mg simvastatin on 
the progression of atherosclerosis in patients with familial hypercholesterolemia and 
found that the addition of ezetimibe to the highest recommended dose of simvastatin, 
although further reducing LDL-C levels, did not result in reduction of the intima-media 
thickness of the carotid artery wall94 (Table 2).  
This result was confirmed by the ARBITER 6-HALTS (Arterial Biology for the 
Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL 
Treatment Strategies in Atherosclerosis) trial that evaluated the effect of adding 
ezetimibe or extended-release niacin to a chronic statin therapy in patients with 
coronary heart disease (CHD) or CHD-equivalent95. The primary endpoint was the 
change in mean carotid intima-media thickness (CIMT): while niacin induced a 
significant regression in mean CIMT, ezetimibe did not change this parameter and 
instead increased cumulative drug exposure resulted in CIMT progression in patients 
treated with ezetimibe95 (Table 2). It appears that the inconclusive results observed 
with these studies are dependent on the starting status of the carotid arteries, i.e if 
the subjects present with IMT values in the normal range the likelihood that an 
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hypolipidaemic treatment will be effective is quite low, thus perhaps explaining the 
findings of the ENHANCE trial. 
The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial has been designed 
to assess the effects of long-term (4.3 years) treatment with ezetimibe+simvastatin in 
patients with asymptomatic, mild-to-moderate aortic-valve stenosis96 (Table 2). This 
intervention resulted in an average reduction of LDL-C of at least 50% compared with 
placebo; however, no effect on aortic-valve events was observed, despite a reduction 
of ischemic cardiovascular events96. The reduction of ischemic events was significant 
in subjects with less severe aortic stenosis at baseline; the lack of effect on ischemic 
events in more severe aortic stenosis at baseline may be explained with the shorter 
duration of lipid-lowering therapy before valve replacement; aortic-valve associated 
events did not decrease even for the mildest degree of aortic stenosis97. 
On the other hand, the Stop Atherosclerosis in Native Diabetics Study (SANDS) 
trial showed that, in subjects with type 2 diabetes, aggressive lipid-lowering treatment 
with ezetimibe+statin induced the regression of carotid IMT, as compared with 
standard lipid-lowering therapy that resulted in a modest carotid IMT progression 98. 
When comparing aggressive statin monotherapy with aggressive statin+ezetimibe, the 
last induced a greater regression of CIMT after 36-month therapy99, indicating that 
ezetimibe is effective in reversing carotid atherosclerosis. A similar result was 
reported in another study showing that adding ezetimibe to statin monotherapy 
significantly reduces LDL-C levels and decreases IMT in a high-risk group of subjects 
with thickened carotid walls100. Similarly, the addition of ezetimibe to the current lipid-
lowering regimen of patients attending vascular prevention clinics resulted in the 
regression of carotid total plaque area101 (Table 2).  
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A significant incremental reduction of coronary plaques has been recently 
reported in subjects who received ezetimibe in addition to usual rosuvastatin 
monotherapy in patients with stable coronary artery disease, with a percent change in 
plaque volume greater in the group of combined therapy compared with rosuvastatin 
alone (-13.2% vs -3.1%, p=0.05)102. In this study, the addition of ezetimibe reduced 
was more effective in reducing not only LDL-C but also TG, non-HDL-C and small 
dense LDL (sd-LDL), being this last associated with increased risk of coronary artery 
disease; the reduction in plaque volume correlated not only with reduction of LDL-C 
but also with levels of sd-LDL at follow-up102 (Table 2). This finding is in agreement 
with the results of another study showing that the addition of ezetimibe to fluvastatin 
therapy resulted in a major increase of the minimum fibrous thickness of lipid-rich 
plaque compared with fluvastatin alone, with a negative correlation between the 
change in minimum fibrous cap thickness and change in LDL-C103. Altogether these 
observations suggest that ezetimibe addition to statin therapy may affect plaque 
stabilization (Table 2). 
NPC1L1 inhibition and cardiovascular disease 
Although a large number of studies showed that adding ezetimibe to a statin 
therapy further reduces LDL-C levels by an additional 23-24%76, 104, to date few 
clinical trials have evaluated the effect of adding ezetimibe to statin therapy on clinical 
cardiovascular outcomes. The Study of Heart and Renal Protection (SHARP) was 
designed to evaluate the effect of the combination ezetimibe+simvastatin in patients 
with moderate-to-severe kidney disease105. Patients randomized to 
ezetimibe+simvastatin or to placebo were followed-up for 4.9 years; LDL-C-lowering 
with ezetimibe+simvastatin resulted in a significantly reduced incidence (-17%) of 
major atherosclerotic events105 although it did not slow kidney disease progression106. 
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When patients with CKD and LDL-C levels above 120 mg/dL (despite statin therapy) 
were randomized to receive double dose of statin or ezetimibe in addition to the usual 
dose of statin, during the first year of follow-up, in spite of similar LDL-C reduction the 
incidence of adverse effects was significantly lower in the combination therapy group 
compared with the high dose of statin107. These findings suggest that combining a 
statin with ezetimibe may help to safely reduce cardiovascular complications of high-
risk patients with chronic kidney disease. 
The Improved Reduction of Outcomes: Vitoryn Efficacy International Trial 
(IMPROVE-IT) evaluated the effect of ezetimibe (10 mg) combined with simvastatin 
(40 mg) or simvastatin (40 mg) alone in patients who had had an acute coronary 
syndrome within the preceding 10 days and LDL-C levels within the range of 
recommended values9. After a median follow-up of 6 years, median time-weighted 
average LDL-C level was significantly lower in the group treated with 
ezetimibe+simvastatin compared with patients treated with simvastatin alone  
(53.7 mg/dL vs 69.5 mg/dL, p<0.001); in addition, a higher proportion of patients 
treated with ezetimibe+simvastatin reached a dual goal including a LDL-C level <70 
mg/dL (1.8 mmol/L)9. Also cardiovascular outcomes were improved in the group 
treated with ezetimibe+simvastatin; indeed the primary end point (a composite of 
cardiovascular death, nonfatal myocardial infarction (MI), unstable angina requiring 
hospitalization, coronary revascularization, nonfatal stroke) was lower in 
ezetimibe+simvastatin group than in simvastatin group (32.7% vs 34.7%, p=0.016)9; 
the risk of any myocardial infarction or ischemic stroke were significantly lower in the 
ezetimibe+simvastatin group than in simvastatin group (any MI: 13.1% vs 14.8%, 
p=0.002; IS: 3.4% vs 4.1%, p=0.008), as were other prespecified end points, while 
no differences were observed in terms of safety between the two groups9 (Table 2). 
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The benefits of adding ezetimibe seemed to be more evident in diabetics and in older 
(≥75 years) patients9. A recent analysis of the IMPROVE-IT trial showed that patients 
reaching the dual LDL-C and hs-CRP targets had the lowest absolute and relative risk 
of recurrent events, independently of the pharmacological approach used to achieve 
the target levels108. These findings support the concept that LDL-C lowering per se 
translates into clinical benefits9. 
NPC1L1 inhibition in familial hypercholesterolemia 
Patients with homozygous familial hypercholesterolemia (HoFH) have a very high 
risk of premature coronary artery disease; statins, that represent the main lipid-
lowering drug class, may be effective in some HoFH patients, but this requires the 
presence of an at least in part functional LDLR109, 110. Novel options are becoming 
available for the treatment of HoFH which include apoB gene silencing69 as well as 
MTP inhibitors42 but also inhibitors on NPC1L1. Indeed, the addition of ezetimibe to 
atorvastatin or simvastatin for 12-week induced a significant reduction in LDL-C levels 
(14% to 20.5%) compared with statins alone111. 
In patients with heterozygous FH (HeFH), which exhibit a less severe phenotype 
and a lower cardiovascular risk compared with HoFH, co-administration of ezetimibe 
with a statin resulted in a further decrease of LDL-C levels112. Of note, in this cohort a 
wide inter-individual variability response to ezetimibe was observed; indeed, 
ezetimibe was less effective in statin hyper-responders (who also present with a 
higher cholesterol synthesis and lower cholesterol absorption) and vice versa112. 
However, the addition of ezetimibe to the highest recommended dose of simvastatin 
did not result in a further reduction of the carotid intima-media thickness compared 
with simvastatin alone in patients with FH, despite LDL-C and C-reactive protein levels 
were lowered to a larger extent in patients treated with the combination therapy94. 
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Given that these patients were treated for many years with statins before the study, it 
is possible that the benefit of the therapy had already occurred and the resultant 
fibrotic, calcified lesion may not further benefit of an additional LDL-C lowering113. Of 
note, another study performed in HeFH with a history of acute myocardial infarction or 
with carotid lesions but no history of cardiovascular events treated for 30 months with 
the combination ezetimibe/simvastatin showed a considerable reduction of LDL-C, an 
improvement of lipid profile and inflammatory markers and a significant reduction of 
the mean of the carotid IMT in both groups114.  
 
Other NPC1L1 inhibitors 
To date, ezetimibe represents the only inhibitor of NPC1L1 available for clinical 
use. In an effort to identify new cholesterol absorption inhibitors, some studies have 
evaluated the possibility to obtain ezetimibe analogs with superior ability to inhibit 
cholesterol absorption. In one study, six new amide ezetimibe analogs have been 
synthesized; these compounds exhibited low toxicity and a significant ability to inhibit 
cholesterol uptake in cells overexpressing human NPC1L1; among them, 3 compounds 
were tested also in vivo in mice, showing the ability to reduce hepatic and intestinal 
cholesterol levels115 (Figure 3). The same authors, in a previous study synthesized two 
new amino-ß-lactam derivatives that efficiently inhibited cholesterol absorption 
comparable to ezetimibe116 (Figure 3). 
Although several compounds with structural similarities to ezetimibe were 
designed, few of them were reported to lower cholesterol absorption 96-98. Eight new 
2-azetidinone analogs of ezetimibe have been designed through in silico docking 
experiments with the crystal structure of NPC1L1 and synthesized; some of these 
molecules have significant lipid-lowering effects, comparable to those of ezetimibe117.  
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Conclusions 
Experimental and human genetics evidences point to a critical role for NPC1L1 in 
intestinal cholesterol absorption. NPC1L1 inhibition provides a complimentary 
approach to decrease plasma cholesterol levels beyond statins which inhibit liver 
cholesterol biosynthesis. The possibility of targeting two pathways involved in 
cholesterol body homeostasis allows to maintain statins doses within the lower range 
without affecting the efficacy in reducing LDL-C levels and the risk of cardiovascular 
events. Therefore the pharmaceutical research is highly active in identifying chemical 
requirements to design novel ezetimibe analogs with increased efficiency thus paving 
the road for novel dual therapies to reduce hypercholesterolemia and the associated 
cardiovascular risk. 
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Legends to the Figures 
Figure 1. Structure of human NPC1L1. NPC1L1 contains 13 transmembrane 
domains, comprising a sterol-sensing domain (SSD), a region of 180 amino acids that 
forms five membrane-spanning helices with short intervening loops. The extracellular 
N-terminal domain of NPC1L1 directly binds cholesterol, while ezetimibe binds to the 
loop C. 
Figure 2. Main metabolites of ezetimibe.  
Figure 3. Structures of ezetimibe analogs. 
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Table 1. Effects of ezetimibe added to statins compared with statin monotherapy on 
blood lipids 
 LDL-C TC apoB HDL-C TG Non-HDL-C 
Ballantyne et al. 
104 
      
E10/S80 
A80 
-59.4% 
-5.2% 
* 
-43.3% 
-40.2% 
* 
-48.6% 
-45.2% 
* 
+12.3 
+6.5% 
* 
-35.3% 
-34.8% 
-55.3 
-50.3 
* 
Ballantyne et al.118        
E10/R40 
R40 
-70% 
-57% 
* 
-51% 
-42% 
* 
-56% 
-45% 
* 
+11% 
+9% 
* 
-35% 
-25% 
* 
-67% 
-55% 
* 
Robinson et al.119       
E10/S40 
A40 
-53.9% 
-46% 
* 
-37.3% 
-32.8% 
* 
-41.1% 
-35.8% 
* 
+8.8% 
+4.9% 
* 
-29.5% 
-30% 
 
-48.3% 
-41.4% 
* 
Leiter et al.120       
E10/A40 
A80 
-27% 
-11% 
* 
-17% 
-7% 
* 
-18% 
-8% 
* 
+0% 
-1% 
-12% 
-6% 
* 
-23% 
-9% 
* 
Conard et al.121       
E10/A20 
A40 p 
-31% 
-11% 
* 
-20% 
-7% 
* 
-21% 
-8% 
* 
+3% 
+1% 
 
-18% 
-6% 
 
-27% 
-10% 
* 
Bays et al.122       
E10/R5, 10 
R10,20 
-21% 
-5.7% 
* 
-12.6% 
-3.9% 
* 
-13.8% 
-4.4% 
* 
-0.5% 
+1.7% 
 
-6.3% 
-3.2% 
 
-17.1% 
-5.2% 
* 
Gagné et al.123       
E10/Statin 
Statin 
 
-25% 
-3.7% 
* 
-17% 
-2.3% 
* 
-19% 
-3.5% 
* 
+2.7% 
+1% 
* 
-14% 
-2.9% 
* 
-23% 
-3.1% 
* 
Bays et al.124       
A20→E10/A20 
A20→A40 
 
R10→E10/A20 
R10→R20 
 
-17.4% 
-6.9% 
* 
-17.1% 
-7.5% 
* 
-10.7% 
-3.8% 
* 
-11.8% 
-4.5% 
* 
-9.8% 
-5.4% 
 
-11.9% 
-4.1% 
+0.7% 
+1.7% 
 
+0.1% 
+0.8% 
-5.9% 
-3.1% 
 
-10.2% 
-3.2% 
-15.1% 
-5.8% 
* 
-16.2% 
-6.4% 
* 
Abate et al.125       
DM 
E/S 
A 
 
 
MetS 
E/S 
A 
 
No DM/MetS 
E/S 
A 
 
-56.1% 
-45.9% 
* 
 
-52.6% 
-44% 
* 
 
-52.7% 
-45.7% 
* 
 
-40.7% 
-34.6% 
* 
 
-38.4% 
-33.6% 
* 
 
-37.1% 
-33.2% 
* 
 
-45.0% 
-38.6% 
* 
 
-42.5% 
-37.4% 
* 
 
-42.3% 
-38.2% 
* 
 
+6.4% 
+3.8% 
* 
 
+9.9% 
+6.6% 
* 
 
+7.2% 
+3.0% 
* 
 
-26.9% 
-25.2% 
 
 
-30.7% 
-29.9% 
 
 
-24.2% 
-22.1% 
 
-51.1% 
-42.8% 
* 
 
-48% 
-41.5% 
* 
 
-48.4% 
-42.2% 
* 
E=ezetimibe; A=atorvastatin; S=simvastatin; R=rosuvastatin; DM= diabetes mellitus; MetS=metabolic 
syndrome; *: statistically significant differences between treatments 
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Table 2. Effects of ezetimibe+statin versus statins monotherapies on carotid atherosclerosis or 
major atherosclerotic events. 
 Subjects Duration LDL-C 
(% change from 
baseline) 
Primary outcomes 
Kastelein et al. 
(ENHANCE)94 
   Carotid IMT 
(change from baseline, mm) 
Eze 10mg/Simva 80mg 
Simva 80mg 
FH 24 mo 
 
-55.6% 
-39.1% 
+0.0111±0.0038 
+0.0058±0.0037 
P=0.29 
Villines et al. (ARBITER 
6-HALTS)95  
   Carotid IMT 
(change from baseline, mm) 
Eze 10 mg 
Niacin 2g 
CHD or CHD 
equivalent on 
stable statin 
therapy 
14 mo -22.5% 
-14% 
 
-0.0007±0.0035, NS 
-0.0142±0.0041, P=0.001 
Rossebo et al. (SEAS)96    Aortic valve events 
Eze 10mg/Simva 40mg 
Placebo  
Stenosis of the 
aortic valve 
52 mo -53.8% 
-3.8% 
32.6% 
35.1% 
P=0.73 
Howard et al. 
(SANDS)98 
   
Mean change CIMT (mm) 
Aggressive LLT 
Standard LLT 
 
 
Aggressive Eze+Statin 
Aggressive Statin alone 
T2DM 36 mo -31% 
+1% 
 
 
-31.1% 
-32.3% 
-0.017±0.12 
+0.041±0.14 
P<0.0001 
 
-0.025 
-0.012 
P<0.0001 
Masuda et al.102    % Change in plaque volume  
Eze 10mg/Rosuva 5mg 
Rosuva 5mg 
Stable CAD 6 mo -55.8% 
-36.8% 
 
-13.2% 
-3.1% 
P=0.05 
Habara et al.103  
   Change in the fibrous cap 
thickness (mm) 
Eze 10mg/Fluva 30mg 
Fluva 30mg 
Angina pectoris 9 mo -34.0% 
-8.3% 
P<0.001 
+0.08±0.08 
+0.04±0.06 
P<0.001 
Baigent et al. 
(SHARP)105 
   Major atherosclerotic events 
Eze 10mg+Simva 20mg 
Placebo 
 
CKD 4.9 y -68% 
-14% 
  
11.3% 
13.4% 
(RR 0.83, P=0.0021) 
Cannon et el. 
(IMPROVE-IT)9 
   
Primary endpoints* 
Eze 10mg/Simva 40mg 
Simva 40mg 
 
ACS 6 y -42.8% 
-25.9% 
32.7% 
34.7% 
P=0.016 
FH: familial hypercholesterolemia; CHD: coronary heart disease; T2DM: type 2 diabetes 
mellitus; CAD: coronary artery disease; CKD: chronic kidney disease; ACS: acute coronary 
syndrome 
* Death from cardiovascular causes, major coronary event, or nonfatal stroke 
 
Page 35 of 45
https://mc04.manuscriptcentral.com/crmc
Current Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
COOH 
NH2 
SSD 
Ezetimibe 
Cholesterol  
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Plasma membrane 
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Figure 1 
EZETIMIBE 
Ezetimibe phenolic glucuronide 
90% 
Ezetimibe ketone 
Ezetimibe benzylic glucuronide 
1% 
R=C6H9O6 
Figure 2 
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(2R,3R,4R)-5 
(2S,3R,4R)-6 Cinnamoyl analog 
Benzyl analog 
Phenyl analog 
Figure 3 
EZETIMIBE 
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Reply to comments from Reviewer: 1 
Dear Reviewer #1, thank you for you comments.  
In this revised version of the manuscript we have addressed all aspects raised by you and by 
the other reviewers. Concerning your specific comments, we offer the following reply: 
 
1) Page 5, para2: Is the reference to 'high glucose' to blood levels or a cell medium? 
This is an important section due to the diabetes finding in IMPROVE-IT. The sense 
needs to be clearer i.e. (in vitro versus in vivo findings). 
Sorry for the misunderstanding, these data result from “in vitro” experiments. This is now 
clearly stated in the text. Please see page 6, “Also high glucose levels increase the cellular 
uptake of cholesterol in cultured intestinal cells; this effect is due to the modulation of 
cholesterol transporters present in intestinal epithelial cells, being NPC1L1 and CD36 
upregulated and SR-BI downregulated”. 
 
2) Page 8, para 1: The expression 'Carriers of NPCL1 .... in heterozygosis' is an 
unusual way of saying Carriers of a single mutant allele ...' Should be reworded. 
The sentence has been reworded as follows: “Carriers of a single mutant NPC1L1 allele”.  
 
3) Page 9, para 1: 'This finding was neither confirmed ...' Better with 'not confirmed' 
and the rest of the sentence needs reworded. 
The sentence has been reworded as suggested.  
 
4) Page 12, para1: 'CTT' is not a trial. The reference is to the analysis conducted by 
the CTT collaboration. 
Sorry for the mistake, the sentence has been deleted. 
 
5) Page 12 bottom: The statements here and following relating to the lipid lowering 
with statin monotherapy versus statin plus ezetimibe need reworked to make clear 
the situation where combination therapy is superior. A high potency statin like 
rosuvastatin can be more effective than some combinations of statin and ezetimibe. 
Your point is well taken, we have rephrased the sentence as follows (page 14):”These findings 
have been confirmed in a pooled analysis of over 21,000 subjects from 27 clinical trials that 
compared the effect of statin versus statin plus ezetimibe and showed that the combination 
therapy was more effective at reducing LDL-C levels (treatment difference: -15.1%, 
p<0.0001). Overall, the lipid profile was greatly improved with the combination therapy 
compared to similar statin doses and in most of the cases also when higher statin doses were 
used. Furthermore, safety profiles were comparable among the treatments”. 
 
6) Page 13, para 2: The sentence 'A greater LDL reduction .. added to a statin with 
high potency ...' is not easy to follow for the non-expert reader. This section needs 
revision to make the English clearer and the findings more specific. 
Your suggestion is well taken and the sentence has been revised as follows (page 15): “The 
combination ezetimibe+statin was more effective at reducing LDL-C levels than doubling the 
dose of statins (-24.6% vs -10.9%, respectively)”. 
 
7) Page 14, para 1: Again, the sense (English and scientific) here is difficult to follow 
' In other studies ... in a significantly strongest effect'. 
Your suggestion is well taken and the sentence has been revised as follows (page 16): 
“Indeed, studies designed to evaluate the effect of ezetimibe on inflammatory markers in 
subjects at increased cardiovascular risk showed a decreased expression of markers of 
oxidative stress and inflammation. This may suggest that the beneficial effect of ezetimibe on 
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inflammation could depend on the degree of plasma cholesterol reduction achieved, further 
supporting the correlation between plasma cholesterol and the immuno-inflammatory status”. 
 
8) Page 15, end of para 1: 'This will explain the ENHANCE results' should be 'This is a 
possible explanation for ...' 
Your suggestion is well taken and the sentence has been amended accordingly (page 17): 
“…thus perhaps explaining the findings of the ENHANCE trial”. 
 
9) Page 16, para 2: English usage needs corrected 'treatment determined a slight 
progression ...'. Similarly, in para 3, 'In this study 'more not only ...'.  
The sentences have been reworded as follows (page 18): “….as compared with standard lipid-
lowering therapy that resulted in a modest carotid IMT progression”; “In this study, the 
addition of ezetimibe reduced was more effective in reducing not only LDL-C but also....” 
 
10) Page 19, para 2: Sense again of 'being patients hyper responders ...'. End of para 
- 'massive' is not a good term in science. 
Thank you for your suggestion, the paragraph was reworded as follows (page 21): “Of note, in 
this cohort a wide inter-individual variability response to ezetimibe was observed; indeed, 
ezetimibe was less effective in statin hyper-responders (who also present with a higher 
cholesterol synthesis and lower cholesterol absorption) and vice versa”; 
11) End of para - 'massive' is not a good term in science. 
The sentence has been revised as follows (page 22): “...showed a considerable reduction of 
LDL-C” 
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Reply to comments from Reviewer  2 
 
Dear Reviewer#2, thank you for you comments.  
In this revised version of the manuscript we have addressed all aspects raised by you and by 
the other reviewers. Concerning your specific comments, we offer the following reply: 
 
1) In Figure 1, I suggest the authors to point out that the C-terminus of NPC1L1 is a 
key domain for recruitment of Numb and clathrin/AP2. 
Your point is well taken, the figure has been amended accordingly. 
 
2) Line 34, another paper should be cited: Kwon HJ, et al., The structure of the 
NPC1L1 N-terminal domain in a closed conformation. Plos One, 2011 
The indication that the structure of the NPC1L1 N-terminal domain is in a closed conformation 
was now included. Please see page 5: “The extracellular N-terminal domain of NPC1L1, that in 
the absence of cholesterol is in a closed conformation, directly binds cholesterol, and this 
interaction is essential for NPC1L1-mediated cellular cholesterol uptake”. 
 
3) Line 43, another paper should be cited: Ge L, et al., The cholesterol absorption 
inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell 
Metabolism, 2008. 
Your point is well taken the paper by Ge et al was now included in the manuscript (Reference 
n°21).  
 
4) Page 9, line5, the NPC1L1-gallstone association should be described in a 
separated paragraph  
Your suggestion is well taken, we now divided the two paragraphs and presented the 
association of NPC1L1 LOFs with cardiovascular diseases or with gallstone disease. 
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Reply to comments from Reviewer 3 
 
Dear Reviewer #3, thank you for you comments.  
In this revised version of the manuscript we have addressed all aspects raised by you and by 
the other reviewers. Concerning your specific comments, we offer the following reply: 
 
1) It may be better to generate a table to summarize major clinical outcomes of 
these trials.  
A table summarizing the major clinical outcomes of the clinical trials is now included (Table 2). 
2) Most relevant papers are listed under references section, but many of them are 
not placed at where they should be as original studies.  
Thank you for bringing this point, the references were updated accordingly. 
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Reply to comments from Reviewer: 4 
 
Dear Reviewer #4, thank you for you comments.  
In this revised version of the manuscript we have addressed all aspects raised by you and by 
the other reviewers. Concerning your specific comments, we offer the following reply: 
 
1. In the general description of the cholesterol absorption/biliary secretion pathways 
ABCG5/G8 should be briefly mentioned. 
Your suggestion is well taken, the description of the ABCG5/G8 pathway was now introduced. 
Please see page 4: “Intestinal cholesterol absorption is a complex multistep process regulated 
by multiple genes; among them, NPC1L1, which is involved in cholesterol uptake, and ATP-
binding cassette transporters ABCG5 and ABCG8, that function as heterodimer and promote 
cholesterol efflux into the intestinal lumen for excretion. Defects in the ABCG5/ABCG8 system 
are linked to sitosterolemia, a condition characterized by high plasma levels of dietary sterols 
and premature coronary heart disease”. 
 
2. Ezetimibe increases endogenous cholesterol synthesis, which is thus far not 
discussed in the review. There are several spots in the text, especially where the 
rationale for combining this drug with statins is discussed and when selection of 
potential best therapy responders is mentioned, where I would suggest to touch on 
this issue. 
Thank you for bringing this point, which is now discussed at page 13 “As the maintenance of 
cholesterol homeostasis is critical for several biological processes and cholesterol synthesis and 
absorption are inversely regulated to maintain cholesterol balance, it is not surprising that the 
inhibition of endogenous cholesterol absorption activates also a series of mechanistic 
feedbacks resulting in increased endogenous cholesterol synthesis. Thus, while statins inhibit 
hepatic synthesis of cholesterol and increase cholesterol absorption markers, ezetimibe 
negatively affects cholesterol absorption but also increases cholesterol synthesis”. 
 
3. Given the increasing interest in PCSK9 inhibitors, the effect of ezetmibe/NPC1L1 
deficiency on PCSK9 might be worth to include. 
This is also a good point and the molecular mechanisms controlling PCSK9 expression as a 
consequence of cholesterol homeostasis are now discussed (page 13): “These pharmacological 
responses may reduce the efficacy of the single drugs, but also  set the stage for combining 
the two pharmacological approaches with the aim of limiting both cholesterol absorption and 
synthesis. In this context, it is worth to mention that statins cause elevation of plasma PCSK9, 
a proprotein convertase that promotes LDLR degradation, and this effect can reduce the 
cholesterol-lowering efficacy of statins. However, in healthy subjects, while a 2-week 
treatment with simvastatin (40 mg) resulted in the upregulation of circulating PCSK9 levels, 
neither ezetimibe alone nor the addition of ezetimibe to simvastatin induced an increase in 
PCSK9 levels. This finding could perhaps be the consequence of the limited absolute LDL-C 
reduction induced by ezetimibe on the top of simvastatin which may not be enough to further 
upregulate PCSK9 expression. In line with this, modest LDL-C lowering such as that observed 
with simvastatin 10 mg does not increase PCSK9 levels”. 
 
4. Stating potential reasons for the discrepancy between LDL-C lowering (12 mgdl) 
and CVD risk reduction (-53%) would add a valuable perspective for the reader (p.8, 
topic: data from reference 6). 
The observation that lifelong exposure to lower LDL-C levels even of a limited magnitude 
results in a greater reduction in CVD risk compared to a similar magnitude of LDL-C reduction 
achieved by pharmacological inhibition is true for all genes involved in lipid metabolism 
(including HMGCoA-Reductase LOF but also PCSK9 LOF). These clearly point to the fact that 
lower LDL-C since birth expose the arteries to a lower risk factor burden, while, when 
pharmacological intervention starts, the arteries have been exposed for decades to the risk 
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factor thus requiring a more intensive lipid lowering to achieve a similar rate of vascular 
protection. This is now described in the main text. Please see page 9: “Extrapolation of genetic 
findings into pharmacology needs some caution, indeed while genetic data provides a lifelong 
NPC1L1 lower expression, pharmacological treatment will start later in life and be limited in 
time. Therefore, the benefit in terms of cardiovascular risk reduction (-53%) as a consequence 
of genetically driven (NPC1L1 inactivating mutations) LDL-C reduction (-12mg/dL) will be 
much higher compared with the cardiovascular risk reduction observed in clinical trials with a 
similar degree of LDL-C reduction. A finding which has been confirmed in all the analyses of 
lipid lowering genes”. 
 
5. Statins appear to increase the risk for T2DM, adding a statement on what is known 
with respect to ezetimibe/NPC1L1 deficiency would be helpful to provide a more 
complete point of view. 
Your point is well taken, this aspect is now mentioned in the manuscript. Please see page 
16: “Besides, it emerged that statin use may impair glucose tolerance and increase the risk of 
new-onset type 2 diabetes, although the benefits of cardiovascular risk reduction still largely 
exceeds the risk of incident diabetes. On the contrary, current data  suggest that ezetimibe 
ameliorates glycemic control and insulin sensitivity. However, conclusive results are still 
lacking, as most clinical trials did not evaluate the impact of ezetimibe on glucose metabolism 
and commonly tested the effect of ezetimibe in combination with a statin. An analysis of the 
IMPROVE-IT trial suggests that type 2 diabetic patients with a recent acute coronary syndrome 
may benefit from the addition of ezetimibe to a statin therapy: in fact, in these subgroup of 
patients, ezetimibe added to a statin lowered LDL-C more than a statin alone (43 mg/dL vs 23 
mg/dL) and reduced the relative cardiovascular risk by 14%. In non-diabetics this effect was 
less evident, with a 2% relative risk reduction” 
 
6. Extending the readers view from apoB-containing lipoproteins to HDL, some 
mention of the impact of NPC1L1/ezetimibe on RCT should be included, since both, 
the hepatic (although not in rodents) and the intestinal compartment of RCT are 
affected by NPC1L1.This might also be pertinent to my point 4 above. 
Thank you for bringing this point which is now discussed in the text. Please see page 12 : 
“The reduction of cholesterol absorption, promotes, as a feedback mechanism to maintain 
cholesterol homeostasis, the increase of reverse cholesterol transport (RCT), a process 
involved in the transport of  cholesterol from peripheral cells back to the liver. This mechanism 
is common in mice genetically manipulated to present reduced cholesterol absorption, but is 
also observed in mice and hamsters following ezetimibe administration. These findings suggest 
that the inhibition of cholesterol absorption may exert an atheroprotective effects also by 
promoting the removal of cholesterol excess from peripheral tissues”. 
 
7. Please carefully re-edit for punctuation, typos and use of English language. 
A careful editing was performed. 
 
Minor points: 
 
1. Please cite the primary references for the statements on p.6, lines 44-53. 
The primary references were introduced. 
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Reviewer: 5 
 
Dear Reviewer #5, thank you for you comments.  
In this revised version of the manuscript we have addressed all aspects raised by you and by 
the other reviewers. Concerning your specific comments, we offer the following reply: 
 
Comments are necessary for the abstract: 
 
•    Line 1: "….either endogenous production or intestinal absorption…" 
•    Line 6: "molecules" instead of "component" 
•    Line 8: no komma after "statin therapy" 
•    4th line from bottom: "effects" instead of "effect" 
The abstract was amended as per your suggestion. 
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